Antabio

French tech company | Builders Republic

About

Clinical-stage biotech developing antibiotics against drug-resistant Gram-negative hospital infections — its lead MEM-ANT3310 pairs the carbapenem meropenem with an in-house beta-lactamase inhibitor to restore activity against carbapenem-resistant pathogens like Acinetobacter, Enterobacterales, and Pseudomonas.

Key facts

Status
Active
Sectors
Healthcare & Life Sciences
Latest stage
Series B
Founded
2009
City
LABEGE
Region
Occitanie
Legal name
ANTABIO
SIREN
517511291
Tracked rounds
1
Amount raised
25 M€ raised since 2020

Funding rounds

  • Series B — 2023

Investors